Biosimilar & First-in-Class Antibody
Prestige BioPharma invests its expertise and resources in the development of biosimilars and new first-in-class antibody therapeutics.
PBP’s current biosimilar portfolio includes:
HD204 (Avastin Biosimilar)
PBP1502 (Humira Biosimilar)
PBP’s current first in class antibody therapeutics portfolio includes:
PBP1510 Anti-PAUF Antibody for Pancreatic Cancer
PBP1710 Anti-CTHRC1 Antibody for Solid Tumors
The first biosimilar of PBP, HD201 Trastuzumab, has been filed and accepted for review with the EMA, projecting market launch in 2021. Prestige BioPharma´s next products in line include a Bevacizumab biosimilar (HD204) in Phase III, an Adalimumab biosimilar (PBP1502) in Phase I, and an innovative anti-PAUF mAb (PBP1510) for the treatment of pancreatic cancer in Phase I stages. Manufacturing facilities for global commercial supply are located in Osong, South Korea.
| Drug | Category | Indication |
|---|---|---|
| HD201 | Biosimilar, Trastuzumab (Herceptin) | Breast Cancer, Gastric Cancer |
| HD204 | Biosimilar, Bevacizumab (Avastin) | Solid Tumors |
| PBP1502 | Biosimilar, Adalimumab (Humira) | Arthritis |
| PBP1510 | First In Class Antibody, Ulenistamab | Pancreatic Cancer, Ovarian Cancer |
| PBP1601 | Biosimilar, Denosumab (Prolia) | Bone Loss, Osteoporosis |
| PBP1602 | Biosimilar, Aflibercept (Eylea) | Macular Edema, Metastatic Colorectal Cancer, Retinopathy |
| PBP1603 | Biosimilar, Eculizumab (Soliris) | Atypical Haemolytic Uremic Syndrome, Paraoxysmal Nocturnal Hemoglobinuria |
| PBP1701 | Biosimilar, Ipilimumab (Yervoy) | Metastatic Melanoma, Unresectable Melanoma |
| PBP1710 | First In Class Antibody | Solid Tumors |
| PBP1801 | Biosimilar, Pertuzumab (Perjeta) | Breast Cancer |
| PBP2001 | Biosimilar, Ramucirumab (Cyramza) | Metastatic/Gastric junction adenocarcinoma |
| PBP2002 | Biosimilar, Natalizumab (Tysabri) | Active Crohn's disease |
| PBP2101 | Biosimilar, Nivolumab (Opdivo) | Metastatic urothelial carcinoma |
| PBP2102 | Biosimilar, Pembrolizumab (Keytruda) | Metastatic/Unresectable melanoma |
| IDC001 | First In Class Bispecific Antibody | Pancreatic cancer, Ovarian cancer |
| IDC002 | First In Class Bispecific Antibody | Pancreatic cancer, Ovarian cancer |
| IDC003 | First In Class Bispecific Antibody | Solid tumors |
| IDC004 | First In Class Bispecific Antibody | Pancreatic cancer, Ovarian cancer |
| IDC005 | First In Class Bispecific Antibody | Solid tumors |
| IDC006 | First In Class Bispecific Antibody | Breast cancer, Metastatic gastric cancer |
| IDC007 | First In Class Bispecific Antibody | Viral Infectious disease |
| IDC008 | First In Class Bispecific Antibody | Pancreatic cancer, Ovarian cancer |
| IDC009 | First In Class Bispecific Antibody | Pancreatic cancer, Ovarian cancer |
Development Stage
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
- HD201 TRASTUZUMAB BIOSIMILAR
INDICATION: BREAST CANCER, GASTRIC CANCER - HD204 BEVACIZUMAB BIOSIMILAR
INDICATION: SOLID TUMORS - PBP1502 ADALIMUMAB BIOSIMILAR
INDICATION: ARTHRITIS - PBP1510 First-In-Class ANTIBODY
INDICATION: PANCREATIC CANCER - PBP1601 DENOSUMAB BIOSIMILAR
INDICATION: BONE LOSS OSTEOPOROSIS - PBP1602 AFLIBERCEPT BIOSIMILAR
INDICATION: MACULAR EDEMA, METASTATIC COLORECTAL CANCER, RETINOPATHY - PBP1603 ECULIZUMAB BIOSIMILAR
INDICATION: ATYPICAL HAEMOLYTIC UREMIC SYNDROME, PAROXYSMAL NOCTURNAL HEMOGLOBINURIA - PBP1701 IPILIMUMAB BIOSIMILAR
INDICATION: METASTATIC MELANOMA, UNRESECTABLE MELANOMA - PBP1710 First-In-Class ANTIBODY
INDICATION: SOLID TUMORS - PBP1801 PERTUZUMAB BIOSIMILAR
INDICATION: BREAST CANCERS - PBP2001 RAMUCIRUMAB BIOSIMILAR
INDICATION: METASTATIC/GASTRIC JUNCTION ADENOCARCINOMA - PBP2002 NATALIZUMAB BIOSIMILAR
INDICATION: ACTIVE CROHN'S DISEASE - PBP2101 NIVOLUMAB BIOSIMILAR
INDICATION: METASTATIC UROTHELIAL CARCINOMA - PBP2102 PEMBROLIZUMAB BIOSIMILAR
INDICATION: METASTATIC.UNRESECTABLE MELANOMA
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3